Abstract:Next-generation sequencing has made possible the detection of rare variant (RV) associations with quantitative traits (QT). Due to high sequencing cost, many studies can only sequence a modest number of selected samples with extreme QT. Therefore association testing in individual studies can be underpowered. Besides the primary trait, many clinically important secondary traits are often measured. It is highly beneficial if multiple studies can be jointly analyzed for detecting associations with commonly measured traits. However, analyzing secondary traits in selected samples can be biased if sample ascertainment is not properly modeled. Some methods exist for analyzing secondary traits in selected samples, where some burden tests can be implemented. However p-values can only be evaluated analytically via asymptotic approximations, which may not be accurate. Additionally, potentially more powerful sequence kernel association tests, variable selection-based methods, and burden tests that require permutations cannot be incorporated. To overcome these limitations, we developed a unified method for analyzing secondary trait associations with RVs (STAR) in selected samples, incorporating all RV tests. Statistical significance can be evaluated either through permutations or analytically. STAR makes it possible to apply more powerful RV tests to analyze secondary trait associations. It also enables jointly analyzing multiple cohorts ascertained under different study designs, which greatly boosts power. The performance of STAR and commonly used RV association tests were comprehensively evaluated using simulation studies. STAR was also implemented to analyze a dataset from the SardiNIA project where samples with extreme low-density lipoprotein levels were sequenced. A significant association between LDLR and systolic blood pressure was identified, which is supported by pharmacogenetic studies. In summary, for sequencing studies, STAR is an important tool for detecting secondary-trait RV associations.

TRIO RVEMVS: A Bayesian framework for rare variant association analysis with expectation-maximization variable selection using family trio data

Inferring disease risk genes from sequencing data in multiplex pedigrees through sharing of rare variants

A Variational Bayes Discrete Mixture Test for Rare Variant Association

RVTESTS: an Efficient and Comprehensive Tool for Rare Variant Association Analysis Using Sequence Data.

TrioMDR: Detecting SNP Interactions in Trio Families with Model-Based Multifactor Dimensionality Reduction.

Approach of Fusing Multiple Tests to Analyzing Rare Genetic Variants

Efficient Mining of Variants from Trios for Ventricular Septal Defect Association Study

A Robust Model-free Approach for Rare Variants Association Studies Incorporating Gene-Gene and Gene-Environmental Interactions

A Probabilistic Method for Identifying Rare Variants Underlying Complex Traits

Methods for Association Analysis and Meta‐Analysis of Rare Variants in Families

Detecting Disease Variants in Case-Parent Trio Studies Using the Bioconductor Software Package Trio

Deviation from baseline mutation burden provides powerful and robust rare-variants association test for complex diseases

Integration of variant annotations using deep set networks boosts rare variant association testing

RetroFun-RVS: a retrospective family-based framework for rare variant analysis incorporating functional annotations

A Robust and Powerful Set-Valued Approach to Rare Variant Association Analyses of Secondary Traits in Case-Control Sequencing Studies.

A Unified Framework for Detecting Rare Variant Quantitative Trait Associations in Pedigree and Unrelated Individuals Via Sequence Data

A unified method for detecting secondary trait associations with rare variants: application to sequence data.

Bayesian model comparison for rare-variant association studies

Estimating Genetic Effects and Quantifying Missing Heritability Explained by Identified Rare-Variant Associations

Rare Variants Analysis by Risk-Based Variable-Threshold Method

Rare variant effect estimation and polygenic risk prediction